MDxHealth Posts Preliminary 2025 Results, Expects Revenue Growth Of 26% To 28% In 2026

MDxHealth reported preliminary Q4 2025 revenue of ~$30.5M (up 23% YoY from $24.7M) and projected full-year 2025 revenue of $109M (up 21% from $90M), driven by a 128% increase in liquid-based units (27,486 in Q4) following the Exosome Diagnostics integration. The company ended 2025 with $29M cash, issued 2026 guidance of $137M–$140M (growth of 26%–28%) and targets a 10% adjusted EBITDA margin run rate by year-end 2026. MDxHealth amended earnout terms for the 2022 GPS acquisition, scheduling cash payments of $15M (2026), $18M (2027) and $21.5M (2028) and issuing Exact Sciences warrants for 3M shares at $5.265, while the stock trades around $3.43 (closed) / $3.50 (pre-market).

Analysis

Market structure: MDxHealth (MDXH) is the direct winner — 21% FY growth and 26–28% 2026 guidance point to expanding pricing and share for liquid-based ExoDx tests (liquid units +57% Y/Y). Tissue-facing competitors lose relative pricing power as clinicians shift to non-invasive testing; Exact Sciences (EXAS) is a secondary beneficiary via warrants but faces potential share pressure if it monetizes exposure. The 128% quarterly jump in liquid units signals demand shock toward liquid biopsies, tightening provider capacity for high-throughput lab services and raising short-term reagent/processing leverage.

Risk assessment: Key tail risks are regulatory/reimbursement reversals (CMS/NCD/Local Coverage) and an operational integration misstep that slows ExoDx conversion; both could erase the 26–28% growth expectation within quarters. Financial risk: MDXH ends 2025 with $29M cash against $15M–$21.5M earnouts in 2026–28 and only a 10% adj. EBITDA run-rate target for 2026 — likely necessitating a financing if margins don’t expand to ~15% or revenues exceed guidance by >10% in 2026. Watch 90-day cash burn, monthly billings cadence, and any equity/convertible raises as immediate catalysts.

Trade implications: Consider a modest long (2–3% NAV) in MDXH to capture re-rate into 2026 guidance but size for dilution risk; hedge with a 6–9 month call spread to cap premium or buy ~50% position protection via 6-month puts 20–25% OTM. Pair trade: long MDXH, short EXAS (smaller notional, ~1% NAV) to hedge sentiment volatility around the earnout/warrant flow. Rotate sector exposure toward molecular diagnostics leaders and away from legacy tissue-pathology names; expect options IV to rise into quarterly prints and the next reimbursement decision.

Contrarian angles: Consensus is underweight the cash/earnout squeeze — the warrant issuance defers dilution risk to execution but does not remove cash obligations; a financing or covenant event would be a binary downside. Conversely, consensus may be underestimating sustained unit-price power for liquid diagnostics; if MDXH achieves >10% adj. EBITDA and revenue beats by >10% in H1 2026, upside could be 30–60% from current levels. Historical parallel: M&A-driven diagnostics rollups often re-rate only after durable reimbursement and 2+ quarters of margin expansion — don’t pay up before those proofs.

Key Decisions for Investors

• Establish a tactical long position in MDXH equal to 2–3% of NAV within 2–6 weeks, targeting a 30–60% upside if MDXH hits its $137–140M 2026 guidance and exits 2026 at ~10% adj. EBITDA; set a hard stop-loss at 25% below entry or on any announced equity raise.
• Hedge the MDXH long with a defined-risk options trade: buy a 6–9 month $4/$6 (or nearest strikes) call spread sized to cover 50–75% of the position to limit premium outlay, or alternatively buy 6-month puts 20–25% OTM covering 50% notional as protection against a financing/cash-runway shock.
• Initiate a small pair trade: long MDXH (2% NAV) vs short EXAS (1% NAV) to hedge sentiment/dilution risk from Exact Sciences' warrants; reduce the short if EXAS announces material selling/monetization of warrants or if MDXH equity issuance is confirmed.
• Monitor three specific catalysts in the next 30–90 days before increasing size: (1) monthly billing cadence showing sustained >20% Y/Y liquid unit growth, (2) cash balance and quarterly guidance consistency, and (3) any CMS/reimbursement announcements — if any of these fail, reduce MDXH exposure to zero.